Developer docs
API playgroundTry for free, no card

Search company profiles

NeoImmuneTech

Full company profile

uuid0002axm

Namestring
NeoImmuneTech
Legal namestring
NeoImmuneTech, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

NeoImmuneTech, Inc. is a clinical-stage biopharmaceutical company founded in January 2014 and headquartered in Rockville, Maryland, with a wholly-owned Korean subsidiary (NeoImmuneTech Co., Ltd., established August 2019) and a Poland subsidiary (May 2024). The company is publicly listed on Korea Exchange KOSDAQ (ticker 950220) since March 2021, trading as Depositary Receipts at a 1:5 ratio. It develops T cell-centered immunotherapeutics for cancer and infectious diseases, anchored by NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein built on Genexine-licensed HyFc technology that functions as a T cell amplifier — clinical data show up to 4-fold increases in CD4+/CD8+ T cells and up to 50-fold increases in stem-cell memory CD8+ T cells. The pipeline extends through the proprietary NEOBASE heterodimer Fc platform for bispecific antibodies and preclinical candidates NT2020 (PROTAC-based T cell activator), NT3020 (CD3xTAA T cell engager), and NT5010 (eTreg depletor for tumor microenvironment modification). NT-I7 has secured four FDA and two EMA Orphan Drug Designations across Acute Radiation Syndrome, glioblastoma, pancreatic cancer, PML, and ICL.

The company operates a dual revenue model. The first stream is out-licensing NT-I7 and pipeline assets to global pharmaceutical partners — Roche (TECENTRIQ combinations in NSCLC and high-risk skin cancer), Merck (KEYTRUDA combinations in solid tumors), Bristol Myers Squibb (OPDIVO combinations in gastric cancer), and Immunocore (KIMMTRAK/ImmTAC TCR combinations) — generating upfront payments, development milestones, and royalties. The second stream is direct commercialization of Endari (FDA-approved L-glutamine oral powder for sickle cell disease) in the United States, its territories, and Canada, secured through a December 2025 License and Exclusive Distribution Agreement with Emmaus Life Sciences, with US sales launched in June 2026 after obtaining Maryland state licensing in May 2026. Endari targets an estimated ~100,000 US sickle cell patients.

Customers span large pharmaceutical partners (co-development collaborators), academic medical centers including MD Anderson, Mayo Clinic, Washington University School of Medicine in St. Louis, UCSF, and NIH/NIAID (clinical trial collaborators and BARDA program participants), and — via the Endari franchise — sickle cell disease patients and payers in the North American market. Capital structure includes a KOSDAQ IPO (March 2021), a ~53.2 billion KRW (~$39M USD) rights offering and public offering in September 2025, and a 5-to-1 stock consolidation effective May 2026; ownership ties to Genexine (original NT-I7 licensor) and Emmaus Life Sciences (Endari partner with equity stake) remain material.

Short descriptiontext

NeoImmuneTech is a clinical-stage biopharmaceutical company developing T cell-centered immunotherapies led by NT-I7 (a long-acting IL-7 fusion protein), with a pipeline spanning oncology combinations, rare immune deficiencies, and direct commercialization of Endari for sickle cell disease in North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
T cell immunotherapy, IL-7 fusion protein, immuno-oncology therapeutics, T cell amplifier platform, orphan drug biologics
Industry3 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Endari (L-glutamine oral powder) product sales
TypeOne Time License
Description

NeoImmuneTech directly commercializes Endari, an FDA-approved sickle cell disease treatment, in the United States, its territories, and Canada following a License and Exclusive Distribution Agreement with Emmaus Life Sciences (signed December 2025, effective Q2 2026). The company also holds rights to generic equivalents and manages pricing strategy, brand operations, and generic (AG) utilization decisions for the North American market. Emmaus receives upfront payments and ongoing royalties on product sales.

2Out-licensing and co-development fees (NT-I7 and pipeline)
TypeLicensing Royalties
Description

NeoImmuneTech generates revenue through licensing agreements with global pharmaceutical companies for co-development and commercialization of NT-I7 and other pipeline assets. Partners include Roche (TECENTRIQ combinations), Merck (KEYTRUDA combinations), Bristol Myers Squibb (OPDIVO combinations), and others. Revenue streams include upfront payments, milestone payments tied to clinical/regulatory achievements, and royalties on product sales.

globenewswire.com
3Royalties from Endari distribution agreement
TypeLicensing Royalties
Description

Under the licensing arrangement with Emmaus Life Sciences, Emmaus pays NeoImmuneTech royalties based on Endari product sales in North America, in addition to upfront payments.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NeoImmuneTech is a clinical-stage biopharmaceutical company that develops and commercializes T-cell-centered novel immunotherapeutics, centered on NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein that amplifies T-cell numbers and function for cancer and infectious disease treatment. The company also directly commercializes Endari (L-glutamine oral powder), an FDA-approved sickle cell disease treatment, in North America under a licensing agreement with Emmaus Life Sciences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 25% reduction in sickle cell crises; 33% decrease in hospitalizations (Endari, FDA-approved 2017)
+6 more records
Product overview1 text field

NeoImmuneTech operates as a T-cell focused immunotherapy company with a pipeline centered on its core platform technology and multiple therapeutic programs. The core product is NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein that functions as a T-cell amplifier, combined with proprietary platform technologies including the NEOBASE heterodimer Fc platform for bispecific antibody development. The company is expanding into commercialized products through the acquisition of Endari distribution rights for sickle cell disease treatment in North America. The development pipeline includes NT2020 (T-cell Activator using PROTAC), NT3020 (T-cell Engager), and NT5010 (TME Modifier), covering multiple T-cell focused therapeutic approaches for cancer and infectious diseases.

Product and service4 records
1NT-I7 (efineptakin alfa)
CategoryCore T-cell Amplifier Biologic
Description

Long-acting human interleukin-7 (rhIL-7-hyFc) fusion protein functioning as a T-cell amplifier that enhances T-cell numbers and immunological function by promoting proliferation and survival of naive and memory T-cells. Indicated for cancer immunotherapy (solid tumors and hematologic malignancies in combination with checkpoint inhibitors, CAR-T, TCR therapies) and infectious diseases including PML, ICL, and ARS.

2Endari (L-glutamine oral powder)
CategorySickle Cell Disease Therapeutics
Description

FDA-approved (July 2017) prescription L-glutamine oral powder for treating sickle cell disease in patients five years and older. Demonstrated 25% reduction in sickle cell crises and 33% decrease in hospitalizations in clinical studies. Distributed in the United States, its territories, and Canada following a License and Exclusive Distribution Agreement with Emmaus Life Sciences.

3NEOBASE Platform
CategoryBispecific Antibody Platform Technology
Description

Proprietary next-generation heterodimer Fc platform technology for developing bispecific antibodies and multi-specific antibodies with enhanced structural stability and immune response promoting capabilities. Enables flexible arrangement of various antigen-targeting sequences and is currently used in NT3020 (T-cell engager) development.

4NT2020 (T-cell Activator)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-22
Description

Joint research collaboration evaluating NT-I7 with Immunocore's ImmTAC platform (KIMMTRAK/tebentafusp) for TCR-based cancer immunotherapy. Research results presented at ASCO 2026, demonstrating that IL-7 enhances ImmTAC-mediated tumor killing, improves T cell fitness (increased naive/stem-like T cells, decreased exhaustion markers), and increases T cell-mediated IFNγ secretion. Immunocore is a NASDAQ-listed UK-based biotech (~$400M annual revenue, ~$800M cash) and pioneer of TCR-based cancer therapy with KIMMTRAK.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-30
Description

License and Exclusive Distribution Agreement granting NeoImmuneTech exclusive rights to market, sell, and distribute Endari (FDA-approved sickle cell disease treatment) and related generic equivalents in the United States, its territories, and Canada. Emmaus receives upfront payment and ongoing royalties. The agreement aims to expand commercialization beyond the US's mature market into regions with greater growth potential. Implementation expected Q2 2026. In June 2026, the agreement was further optimized with some payment obligations converted to equity investment, minimizing cash outflow and aligning incentives between both parties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-01
Description

Co-development agreement for TECENTRIQ (atezolizumab) and NT-I7 combination therapy targeting non-small cell lung cancer (NSCLC) (NIT-119, IND approved January 2020). Also covers high-risk skin cancer combination (IND initiated April 2018). Roche is a major global pharmaceutical company providing its PD-L1 checkpoint inhibitor for combination clinical trials with NT-I7.

4Bristol Myers Squibb (BMS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-01
Description

Co-development agreement for OPDIVO (nivolumab) and NT-I7 combination therapy targeting gastric cancer, initiated January 2020. Combines BMS's PD-1 checkpoint inhibitor with NT-I7 for immuno-oncology applications.

neoimmunetech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-01
Description

Co-development agreement for KEYTRUDA (pembrolizumab) and NT-I7 combination therapy targeting solid tumors, initiated December 2019. Combines Merck's PD-1 checkpoint inhibitor with NT-I7's T cell amplification technology across multiple cancer indications.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2015-06-01
Description

License-in agreement from Genexine for NT-I7 (efineptakin alfa, rhIL-7-hyFc) in the Americas and Europe, established June 2015. NeoImmuneTech acquired rights to develop and commercialize NT-I7 in these territories. Additional co-development collaboration for head and neck cancer triple combination (NT-I7 + GX-188E + KEYTRUDA) with Phase 2 expansion cohort approval in January 2024. Genexine is a Korean biopharmaceutical company (GX-I7 is the Korean development designation).

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Contract for ARS (Acute Radiation Syndrome) treatment development signed December 2022 with NIAID. Collaboration involves preclinical animal model studies for NT-I7 as an ARS countermeasure, supporting NeoImmuneTech's BARDA BAA program participation. NIAID is part of the US National Institutes of Health.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Clinical trial collaboration and research partnership with MD Anderson Cancer Center for NT-I7 development. MD Anderson is one of the world's leading cancer centers, providing clinical research capabilities and scientific expertise for NT-I7 clinical programs.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration with UCSF for NT-I7 clinical development. Scientific Advisory Board member Dr. Hyunseok Kang (강현석) is a professor at UCSF Department of Oncology and conducts head and neck cancer clinical research with NT-I7 monotherapy (NIT-115).

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Investigator-initiated trial collaboration for NIT-126 (CD19 CAR-T + NT-I7 for LBCL) and NIT-112 (CAR-T + NT-I7). Led by Zachary D. Crees and John F. DiPersio at Washington University, a leading institution in CAR-T cell therapy research.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing engineered TCR-T cell therapies for solid tumors (e.g., Tecelra for synovial sarcoma). Comparable to NeoImmuneTech in its T cell-centered immuno-oncology focus and combination-therapy development model with checkpoint inhibitors.

TypeDirect peer
Description

NASDAQ-listed UK biotech ($400M revenue, KIMMTRAK/tebentafusp) pioneering TCR-based cancer immunotherapy. Direct NT-I7 combination collaborator and a peer in TCR-driven T cell amplification, with overlapping scientific advisors and joint ASCO 2026 presentations.

TypeEmerging player
Description

Biotech developing bispecific and multifunctional antibody therapeutics using its proprietary Azymetric and EFECT platforms. Closely comparable platform-technology peer to NeoImmuneTech's NEOBASE heterodimer Fc platform for bispecific antibody development.

4Bristol Myers Squibb
TypeBroad incumbent
Description

Global pharma with leading checkpoint inhibitor (Opdivo), CAR-T franchises (Breyanzi, Abecma), and broad T cell immunotherapy portfolio. Both a direct collaboration partner (NT-I7 + Opdivo in gastric cancer) and a broad incumbent competitor with internal T cell programs.

TypeDirect peer
Description

Clinical-stage biotech developing allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors. Directly comparable as a T cell therapy peer focused on improving CAR-T persistence and broadening access - the same clinical problem NT-I7's CAR-T combination programs (NIT-126, NIT-128) aim to address.

TypeBroad incumbent
Description

Major US biopharma with deep immuno-oncology presence (Libtayo PD-1 antibody) and cytokine-based therapeutic platforms (REGN-COV antibodies). Comparable as an incumbent developing T cell-targeted combination therapies and as a potential large-pharma partner/competitor for combination strategies.

TypeDirect peer
Description

Korean biopharmaceutical company that originally developed and licensed-out NT-I7 (known as GX-I7 in Korea) to NeoImmuneTech for the Americas and Europe. Direct counterparty for the core asset and Chairman-level overlap; comparable as a clinical-stage cytokine/immunomodulator developer with parallel geographic rights to NT-I7.

TypeEmerging player
Description

Clinical-stage oncology company developing T cell engagers (e.g., CLN-978, CD19xCD3) and immune-modulating therapeutics. Comparable as an emerging immuno-oncology player with T cell engager technology that intersects with NeoImmuneTech's NT3020 bispecific program.

TypeEmerging player
Description

Clinical-stage biotech developing conditionally activated cytokine-based immunotherapies (e.g., IL-2, IL-12 prodrugs) for oncology. Comparable as a small-cap peer using engineered cytokines to amplify T cell responses in the tumor microenvironment, similar mechanistic approach to NT-I7.

TypeEmerging player
Description

Clinical-stage biotech with bispecific antibody programs (CTX-009, CTX-1121) targeting oncology. Comparable to NeoImmuneTech in developing T cell-engaging bispecific antibodies and combination immunotherapies in solid tumors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeoImmuneTech

Cancer Immunotherapyneoimmunetech.com

NeoImmuneTech is a clinical-stage biopharmaceutical company developing T cell-centered immunotherapies led by NT-I7 (a long-acting IL-7 fusion protein), with a pipeline spanning oncology combinations, rare immune deficiencies, and direct commercialization of Endari for sickle cell disease in North America.

What NeoImmuneTech does

NeoImmuneTech, Inc. is a clinical-stage biopharmaceutical company founded in January 2014 and headquartered in Rockville, Maryland, with a wholly-owned Korean subsidiary (NeoImmuneTech Co., Ltd., established August 2019) and a Poland subsidiary (May 2024). The company is publicly listed on Korea Exchange KOSDAQ (ticker 950220) since March 2021, trading as Depositary Receipts at a 1:5 ratio. It develops T cell-centered immunotherapeutics for cancer and infectious diseases, anchored by NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein built on Genexine-licensed HyFc technology that functions as a T cell amplifier — clinical data show up to 4-fold increases in CD4+/CD8+ T cells and up to 50-fold increases in stem-cell memory CD8+ T cells. The pipeline extends through the proprietary NEOBASE heterodimer Fc platform for bispecific antibodies and preclinical candidates NT2020 (PROTAC-based T cell activator), NT3020 (CD3xTAA T cell engager), and NT5010 (eTreg depletor for tumor microenvironment modification). NT-I7 has secured four FDA and two EMA Orphan Drug Designations across Acute Radiation Syndrome, glioblastoma, pancreatic cancer, PML, and ICL.

The company operates a dual revenue model. The first stream is out-licensing NT-I7 and pipeline assets to global pharmaceutical partners — Roche (TECENTRIQ combinations in NSCLC and high-risk skin cancer), Merck (KEYTRUDA combinations in solid tumors), Bristol Myers Squibb (OPDIVO combinations in gastric cancer), and Immunocore (KIMMTRAK/ImmTAC TCR combinations) — generating upfront payments, development milestones, and royalties. The second stream is direct commercialization of Endari (FDA-approved L-glutamine oral powder for sickle cell disease) in the United States, its territories, and Canada, secured through a December 2025 License and Exclusive Distribution Agreement with Emmaus Life Sciences, with US sales launched in June 2026 after obtaining Maryland state licensing in May 2026. Endari targets an estimated ~100,000 US sickle cell patients.

Customers span large pharmaceutical partners (co-development collaborators), academic medical centers including MD Anderson, Mayo Clinic, Washington University School of Medicine in St. Louis, UCSF, and NIH/NIAID (clinical trial collaborators and BARDA program participants), and — via the Endari franchise — sickle cell disease patients and payers in the North American market. Capital structure includes a KOSDAQ IPO (March 2021), a ~53.2 billion KRW (~$39M USD) rights offering and public offering in September 2025, and a 5-to-1 stock consolidation effective May 2026; ownership ties to Genexine (original NT-I7 licensor) and Emmaus Life Sciences (Endari partner with equity stake) remain material.

NeoImmuneTech firmographics

Firmographics
Name
NeoImmuneTech
Legal name
NeoImmuneTech, Inc.
Website
https://neoimmunetech.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
NeoImmuneTech is a clinical-stage biopharmaceutical company developing T cell-centered immunotherapies led by NT-I7 (a long-acting IL-7 fusion protein), with a pipeline spanning oncology combinations, rare immune deficiencies, and direct commercialization of Endari for sickle cell disease in North America.
Ownership category
akta.pro rank

NeoImmuneTech industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • T cell immunotherapy
  • IL-7 fusion protein
  • Immuno-oncology therapeutics
  • T cell amplifier platform
  • Orphan drug biologics

Where NeoImmuneTech is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

NeoImmuneTech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Endari (L-glutamine oral powder) product sales: NeoImmuneTech directly commercializes Endari, an FDA-approved sickle cell disease treatment, in the United States, its territories, and Canada following a License and Exclusive Distribution Agreement with Emmaus Life Sciences (signed December 2025, effective Q2 2026). The company also holds rights to generic equivalents and manages pricing strategy, brand operations, and generic (AG) utilization decisions for the North American market. Emmaus receives upfront payments and ongoing royalties on product sales.
  2. Out-licensing and co-development fees (NT-I7 and pipeline): NeoImmuneTech generates revenue through licensing agreements with global pharmaceutical companies for co-development and commercialization of NT-I7 and other pipeline assets. Partners include Roche (TECENTRIQ combinations), Merck (KEYTRUDA combinations), Bristol Myers Squibb (OPDIVO combinations), and others. Revenue streams include upfront payments, milestone payments tied to clinical/regulatory achievements, and royalties on product sales.
  3. Royalties from Endari distribution agreement: Under the licensing arrangement with Emmaus Life Sciences, Emmaus pays NeoImmuneTech royalties based on Endari product sales in North America, in addition to upfront payments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

NeoImmuneTech product offering

Product offering

Core offering

NeoImmuneTech is a clinical-stage biopharmaceutical company that develops and commercializes T-cell-centered novel immunotherapeutics, centered on NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein that amplifies T-cell numbers and function for cancer and infectious disease treatment. The company also directly commercializes Endari (L-glutamine oral powder), an FDA-approved sickle cell disease treatment, in North America under a licensing agreement with Emmaus Life Sciences.

Product overview

NeoImmuneTech operates as a T-cell focused immunotherapy company with a pipeline centered on its core platform technology and multiple therapeutic programs. The core product is NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein that functions as a T-cell amplifier, combined with proprietary platform technologies including the NEOBASE heterodimer Fc platform for bispecific antibody development. The company is expanding into commercialized products through the acquisition of Endari distribution rights for sickle cell disease treatment in North America. The development pipeline includes NT2020 (T-cell Activator using PROTAC), NT3020 (T-cell Engager), and NT5010 (TME Modifier), covering multiple T-cell focused therapeutic approaches for cancer and infectious diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • NT-I7 (efineptakin alfa) Long-acting human interleukin-7 (rhIL-7-hyFc) fusion protein functioning as a T-cell amplifier that enhances T-cell numbers and immunological function by promoting proliferation and survival of naive and memory T-cells. Indicated for cancer immunotherapy (solid tumors and hematologic malignancies in combination with checkpoint inhibitors, CAR-T, TCR therapies) and infectious diseases including PML, ICL, and ARS.
  • Endari (L-glutamine oral powder) FDA-approved (July 2017) prescription L-glutamine oral powder for treating sickle cell disease in patients five years and older. Demonstrated 25% reduction in sickle cell crises and 33% decrease in hospitalizations in clinical studies. Distributed in the United States, its territories, and Canada following a License and Exclusive Distribution Agreement with Emmaus Life Sciences.
  • NEOBASE Platform Proprietary next-generation heterodimer Fc platform technology for developing bispecific antibodies and multi-specific antibodies with enhanced structural stability and immune response promoting capabilities. Enables flexible arrangement of various antigen-targeting sequences and is currently used in NT3020 (T-cell engager) development.
  • NT2020 (T-cell Activator)

Quantifiable outcome

  • 25% reduction in sickle cell crises; 33% decrease in hospitalizations (Endari, FDA-approved 2017)
  • +6 more outcomes

Companies that use NeoImmuneTech

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

NeoImmuneTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NeoImmuneTech partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered major and core.

  • ImmunocoremajorStrategic or Co-development Partner · 22 May 2026Joint research collaboration evaluating NT-I7 with Immunocore's ImmTAC platform (KIMMTRAK/tebentafusp) for TCR-based cancer immunotherapy. Research results presented at ASCO 2026, demonstrating that IL-7 enhances ImmTAC-mediated tumor killing, improves T cell fitness (increased naive/stem-like T cells, decreased exhaustion markers), and increases T cell-mediated IFNγ secretion. Immunocore is a NASDAQ-listed UK-based biotech (~$400M annual revenue, ~$800M cash) and pioneer of TCR-based cancer therapy with KIMMTRAK.
  • Emmaus Life SciencescoreChannel Partner/ Reseller/ Distributor · 30 December 2025License and Exclusive Distribution Agreement granting NeoImmuneTech exclusive rights to market, sell, and distribute Endari (FDA-approved sickle cell disease treatment) and related generic equivalents in the United States, its territories, and Canada. Emmaus receives upfront payment and ongoing royalties. The agreement aims to expand commercialization beyond the US's mature market into regions with greater growth potential. Implementation expected Q2 2026. In June 2026, the agreement was further optimized with some payment obligations converted to equity investment, minimizing cash outflow and aligning incentives between both parties.
  • RochecoreStrategic or Co-development Partner · 1 October 2020Co-development agreement for TECENTRIQ (atezolizumab) and NT-I7 combination therapy targeting non-small cell lung cancer (NSCLC) (NIT-119, IND approved January 2020). Also covers high-risk skin cancer combination (IND initiated April 2018). Roche is a major global pharmaceutical company providing its PD-L1 checkpoint inhibitor for combination clinical trials with NT-I7.
  • Bristol Myers Squibb (BMS)coreStrategic or Co-development Partner · 1 April 2020Co-development agreement for OPDIVO (nivolumab) and NT-I7 combination therapy targeting gastric cancer, initiated January 2020. Combines BMS's PD-1 checkpoint inhibitor with NT-I7 for immuno-oncology applications.
  • Merck (MSD)coreStrategic or Co-development Partner · 1 December 2019Co-development agreement for KEYTRUDA (pembrolizumab) and NT-I7 combination therapy targeting solid tumors, initiated December 2019. Combines Merck's PD-1 checkpoint inhibitor with NT-I7's T cell amplification technology across multiple cancer indications.
  • GenexinecoreOEM/ Whitelabel/ Licensing Partner · 1 June 2015License-in agreement from Genexine for NT-I7 (efineptakin alfa, rhIL-7-hyFc) in the Americas and Europe, established June 2015. NeoImmuneTech acquired rights to develop and commercialize NT-I7 in these territories. Additional co-development collaboration for head and neck cancer triple combination (NT-I7 + GX-188E + KEYTRUDA) with Phase 2 expansion cohort approval in January 2024. Genexine is a Korean biopharmaceutical company (GX-I7 is the Korean development designation).
  • NIH / NIAID (National Institute of Allergy and Infectious Diseases)majorStrategic or Co-development PartnerContract for ARS (Acute Radiation Syndrome) treatment development signed December 2022 with NIAID. Collaboration involves preclinical animal model studies for NT-I7 as an ARS countermeasure, supporting NeoImmuneTech's BARDA BAA program participation. NIAID is part of the US National Institutes of Health.
  • MD Anderson Cancer CentermajorStrategic or Co-development PartnerClinical trial collaboration and research partnership with MD Anderson Cancer Center for NT-I7 development. MD Anderson is one of the world's leading cancer centers, providing clinical research capabilities and scientific expertise for NT-I7 clinical programs.
  • UCSF (University of California, San Francisco)majorStrategic or Co-development PartnerResearch collaboration with UCSF for NT-I7 clinical development. Scientific Advisory Board member Dr. Hyunseok Kang (강현석) is a professor at UCSF Department of Oncology and conducts head and neck cancer clinical research with NT-I7 monotherapy (NIT-115).
  • Washington University School of Medicine in St. LouismajorStrategic or Co-development PartnerInvestigator-initiated trial collaboration for NIT-126 (CD19 CAR-T + NT-I7 for LBCL) and NIT-112 (CAR-T + NT-I7). Led by Zachary D. Crees and John F. DiPersio at Washington University, a leading institution in CAR-T cell therapy research.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

NeoImmuneTech competitors and assessment

Company assessment

Direct peers

  • Adaptimmune Therapeutics: Clinical-stage biotech developing engineered TCR-T cell therapies for solid tumors (e.g., Tecelra for synovial sarcoma). Comparable to NeoImmuneTech in its T cell-centered immuno-oncology focus and combination-therapy development model with checkpoint inhibitors.
  • Immunocore: NASDAQ-listed UK biotech ($400M revenue, KIMMTRAK/tebentafusp) pioneering TCR-based cancer immunotherapy. Direct NT-I7 combination collaborator and a peer in TCR-driven T cell amplification, with overlapping scientific advisors and joint ASCO 2026 presentations.
  • Allogene Therapeutics: Clinical-stage biotech developing allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors. Directly comparable as a T cell therapy peer focused on improving CAR-T persistence and broadening access - the same clinical problem NT-I7's CAR-T combination programs (NIT-126, NIT-128) aim to address.
  • Genexine: Korean biopharmaceutical company that originally developed and licensed-out NT-I7 (known as GX-I7 in Korea) to NeoImmuneTech for the Americas and Europe. Direct counterparty for the core asset and Chairman-level overlap; comparable as a clinical-stage cytokine/immunomodulator developer with parallel geographic rights to NT-I7.

Emerging players

  • Zymeworks: Biotech developing bispecific and multifunctional antibody therapeutics using its proprietary Azymetric and EFECT platforms. Closely comparable platform-technology peer to NeoImmuneTech's NEOBASE heterodimer Fc platform for bispecific antibody development.
  • Cullinan Oncology: Clinical-stage oncology company developing T cell engagers (e.g., CLN-978, CD19xCD3) and immune-modulating therapeutics. Comparable as an emerging immuno-oncology player with T cell engager technology that intersects with NeoImmuneTech's NT3020 bispecific program.
  • Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated cytokine-based immunotherapies (e.g., IL-2, IL-12 prodrugs) for oncology. Comparable as a small-cap peer using engineered cytokines to amplify T cell responses in the tumor microenvironment, similar mechanistic approach to NT-I7.
  • Compass Therapeutics: Clinical-stage biotech with bispecific antibody programs (CTX-009, CTX-1121) targeting oncology. Comparable to NeoImmuneTech in developing T cell-engaging bispecific antibodies and combination immunotherapies in solid tumors.

Broad incumbents

  • Bristol Myers Squibb: Global pharma with leading checkpoint inhibitor (Opdivo), CAR-T franchises (Breyanzi, Abecma), and broad T cell immunotherapy portfolio. Both a direct collaboration partner (NT-I7 + Opdivo in gastric cancer) and a broad incumbent competitor with internal T cell programs.
  • Regeneron Pharmaceuticals: Major US biopharma with deep immuno-oncology presence (Libtayo PD-1 antibody) and cytokine-based therapeutic platforms (REGN-COV antibodies). Comparable as an incumbent developing T cell-targeted combination therapies and as a potential large-pharma partner/competitor for combination strategies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

NeoImmuneTech social profiles

Digital presence

NeoImmuneTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeoImmuneTech leadership team

Management profile

Number of profiles

Profiles4 records

NeoImmuneTech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

NeoImmuneTech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeoImmuneTech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoImmuneTech

What does NeoImmuneTech do?

NeoImmuneTech is a clinical-stage biopharmaceutical company that develops and commercializes T-cell-centered novel immunotherapeutics, centered on NT-I7 (efineptakin alfa), a long-acting interleukin-7 fusion protein that amplifies T-cell numbers and function for cancer and infectious disease treatment. The company also directly commercializes Endari (L-glutamine oral powder), an FDA-approved sickle cell disease treatment, in North America under a licensing agreement with Emmaus Life Sciences.

Is NeoImmuneTech a public or private company?

NeoImmuneTech is a public company. It is classified as public and is currently operating.

When was NeoImmuneTech founded?

NeoImmuneTech was founded in 2014. It employs 11 to 50 people.

Where is NeoImmuneTech based?

NeoImmuneTech is headquartered in Rockville, United States, in the North America region.

How does NeoImmuneTech make money?

Three revenue lines are on record. Endari (L-glutamine oral powder) product sales are the primary driver. The others are out-licensing and co-development fees (NT-I7 and pipeline) and royalties from Endari distribution agreement.

Who are NeoImmuneTech's main competitors?

Direct peers on record are Adaptimmune Therapeutics, Immunocore, Allogene Therapeutics and Genexine. Emerging players are Zymeworks, Cullinan Oncology, Werewolf Therapeutics and Compass Therapeutics. Broad incumbents are Bristol Myers Squibb and Regeneron Pharmaceuticals.

Does NeoImmuneTech have an API?

No public API is recorded for NeoImmuneTech.

What industry is NeoImmuneTech in?

NeoImmuneTech's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MkNeoImmuneTech licenses NT-I7 in up to $260 mn dealNeoImmuneTech has licensed the U.S. and European rights to its immunotherapy candidate NT-I7 to Tolerance Bio in a deal valued at up to $260 million. NeoImmuneTech will receive a 4 percent equity stake in Tolerance Bio instead of an upfront payment, along with potential milestone payments and royalties tied to clinical and commercial success.The Pharma LetterTolerance Bio in-licenses efineptakin alfa to advance thymus-related therapiesTolerance Bio entered an exclusive license agreement with NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), a clinical-stage long-acting IL-7 fusion protein. The drug will be developed for thymus-related indications in the Americas and Europe.YahooTolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune ResilienceTolerance Bio, Inc. has entered into an exclusive license agreement with NeoImmuneTech to develop and commercialize efineptakin alfa, a clinical-stage long-acting IL-7 fusion protein, in the Americas and Europe. Tolerance Bio plans to initiate Phase 2 clinical trials for the therapy, targeting HIV immunological non-response as an initial indication to evaluate enhancements in thymic function and immune resilience.BioSpaceTolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune ResilienceTolerance Bio licensed efineptakin alfa from NeoImmuneTech for thymus-related indications in the Americas and Europe. The company plans to initiate Phase 2 trials, targeting HIV immunological non-response, with potential milestone payments up to $260 million.Business Wire BlogTolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune ResilienceTolerance Bio, Inc. has entered into an exclusive license agreement with NeoImmuneTech to develop and commercialize efineptakin alfa for thymus-related indications in the Americas and Europe. The deal includes potential milestone payments up to $260 million, equity consideration, and tiered royalties, marking Tolerance Bio's transition to a clinical-stage biotechnology company. Tolerance Bio plans to initiate Phase 2 trials for the therapy, targeting HIV immunological non-response as an initial indication.YahooEmmaus Life Sciences Reports Quarterly Financial ResultsEmmaus Life Sciences, Inc. reported its financial results for the quarter ending June 30, 2026, highlighting a significant increase in net revenues. The company recognized a 124% rise in revenues to $6.3 million, attributed primarily to a licensing agreement with NeoImmuneTech, Inc., which positively affected their operations and reduced expenses. Emmaus also reported a net income of $1.3 million for the quarter, contrasting with a loss in the previous year.Stock TitanEmmaus Life Sciences Earnings: Revenue Up 124% to $6.3MEmmaus Life Sciences, Inc. reported a 124% increase in net revenues for the three months ended June 30, 2026, reaching $6.3 million, primarily due to a license agreement with NeoImmuneTech, Inc. This agreement allows NeoImmuneTech exclusive rights to market, sell, and distribute Emmaus' product Endari for sickle cell disease in the U.S. and Canada. Additionally, Emmaus managed to reduce its operating expenses during the period.Quiver QuantitativeEmmaus Reports $6.3 Million Quarterly Revenue and $1.3 Million Net Income | EMMA Stock NewsEmmaus Life Sciences reported $6.3 million in quarterly net revenue and a $1.3 million net income for the period ended June 30, 2026, marking a significant turnaround from the prior year's net loss. This financial performance was driven by revenue recognition from an upfront payment and royalties under its exclusive distribution agreement with NeoImmuneTech.GlobeNewswireENDARI Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and JapanResearch and Markets published a market analysis report forecasting ENDARI sales from 2026 to 2034, covering the United States, European markets, and Japan. In January 2026, Emmaus Life Sciences licensed exclusive marketing rights for ENDARI in the United States and Canada to NeoImmuneTech. The report highlights ENDARI's clinical benefits, including a 25% reduction in sickle cell crises and 33% decrease in hospitalizations, along with its FDA approval in 2017 as the first new sickle cell disease therapy in nearly two decades.AijournEmmaus Life Sciences Reports Annual Financial ResultsEmmaus Life Sciences reported a 25% decline in net revenues to $12.5 million for 2025 compared to $16.7 million in 2024, citing ongoing competition from generic L-Glutamine in the U.S. market. Despite the revenue decline, the company achieved income from operations of $0.2 million versus a loss of $1.9 million in the prior year, thanks to a 34% reduction in operating expenses; however, net loss widened to $7.2 million from $6.5 million due to increased other expenses. The company announced a strategic shift toward international markets and entered into a license and exclusive distribution arrangement with NeoImmuneTech for its U.S. operations, expected to be fully implemented in Q2.